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Abstract
Objectives: The objectives were to describe the frequency of repeat enrollment within a speciﬁc
exception from informed consent trial testing benzodiazepine treatment of prehospital status epilepticus
and to estimate the effect of repeat enrollments on the analysis of the primary outcome.
Methods: This was a secondary analysis of data collected as part of the Rapid Anticonvulsant Medication
Prior to Arrival Trial (RAMPART), a study comparing intramuscular midazolam to intravenous lorazepam
given by paramedics to patients with prehospital status epilepticus. Subjects in RAMPART achieved a
successful primary outcome if they had cessation of seizures by the time of emergency department
arrival. Data were collected on all subjects, but only the ﬁrst enrollment for each individual was used in
the primary analysis. The patterns of repeat enrollment are described, along with the demographics of
these subjects. In addition, an intraclass correlation coefﬁcient (ICC) was estimated to assess the amount
of within-subject correlation and its effect on the estimated treatment effect when all enrollments are
included in the analysis.
Results: A total of 1,023 enrollments occurred in RAMPART among 893 unique individuals (range of
repeat enrollment observed = two to 14). The ICC for seizure cessation within individual was low at
0.119; when excluding subjects with benzodiazepine crossover, the ICC was 0.094.
Conclusions: In clinical trials of emergency conditions with interval complete resolution, accounting for
repeat enrollments is feasible. The RAMPART experience demonstrated that in this setting the within-
subject correlation is low and can be accounted for at relatively low statistical cost.
ACADEMIC EMERGENCY MEDICINE 2015;22:373–377 © 2015 by the Society for Academic Emergency
Medicine
I n most clinical trials, patients participate once. Intrials of emergency conditions such as status epilep-ticus with early enrollment, patients may inadver-
tently or intentionally be enrolled multiple times. Many
important, high-morbidity emergency conditions recur
in at-risk individuals. Speciﬁc examples include status
asthmaticus, head trauma, and status epilepticus.1 In the
prehospital setting or early in the emergency depart-
ment (ED) visit, evaluations of treatments for such con-
ditions by clinical trials frequently employ exception
from informed consent (EFIC), which makes it more dif-
ﬁcult to prospectively identify potential reenrollers.2
Within a clinical trial, repeated measurements of out-
come data from the same individual may be positively
correlated. Ignoring this correlation may bias the vari-
ance estimate and lead to spurious results.3
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Independence of observations is a key assumption of
many statistical techniques.4 In brief, independence
means that knowledge of a given observation does not
affect the probability distribution of other observations.
In a typical clinical trial, by measuring an outcome in
one patient, the outcome probability distribution of the
other is unaffected. However, independence is com-
monly violated with clustered data. In the case of an
EFIC trial with repeat enrollments, if some patients are
more or less likely to respond to treatment, then addi-
tional enrollments by those patients may not provide
truly independent information. In this case, the extent to
which some patients have either highly refractory or
easily treated status epilepticus can lead to misestima-
tion of the conﬁdence intervals of the treatment effect of
interest.
The planning of clinical trials requires careful con-
sideration regarding the preexisting state of knowl-
edge within the disease, along with the scientiﬁc and
logistical priorities of the actual experiment to be con-
ducted. The ﬁeld of emergency care research is unique
for many reasons; of particular interest within this set-
ting is the potential recurrent nature of serious condi-
tions. As such, one way of addressing the correlation
within subjects who may present with the disease in
question multiple times is to only enroll a patient once
in a clinical trial. On the other hand, practical concerns
may make it challenging to determine that a patient
has been enrolled previously when an intervention is
being delivered under EFIC. A common approach is to
limit to the ﬁrst occurrence of the disease within indi-
vidual, as this will eliminate the possibility of within-
subject correlation biasing the results. Under an EFIC
trial, however, the patient may have repeated exposure
to a research intervention without the prospect of con-
tributing to scientiﬁc knowledge on the primary efﬁ-
cacy outcome. Such repeated enrollments may
contribute information regarding safety, however. As
such, when planning emergency care research it is
important to consider the scientiﬁc, ethical, and logisti-
cal effects of the approach that will be used to account
for repeated presentations with the same condition.
Our objectives were to describe the frequency of
repeat enrollment within a speciﬁc EFIC trial of benzo-
diazepine treatment for prehospital status epilepticus
and the effect of repeat enrollments on the analysis of
the primary outcome.
METHODS
Study Design
The Rapid Anticonvulsant Medication Prior to Arrival
Trial (RAMPART) was a phase 3 randomized, double-
blind, noninferiority clinical trial comparing intrave-
nous (IV) lorazepam to intramuscular midazolam via
autoinjector for prehospital patients with status epilep-
ticus. The design and results of the primary analysis of
RAMPART have been previously published.5 The cur-
rent investigation is a secondary analysis of RAMPART
focused on patients with multiple enrollments. The pri-
mary analysis of RAMPART data only included the ﬁrst
enrollment; however, data on response and follow-up
were collected for subjects who were enrolled multiple
times. Subjects in RAMPART achieved a successful pri-
mary outcome if they had cessation of seizures by the
time of ED arrival. More detailed methods are in Data
Supplement S1 (available as supporting information in
the online version of this paper). The trial was con-
ducted under EFIC for emergency research. Institu-
tional review boards for all entities engaged in the
research approved the protocol.
Study Setting and Population
RAMPART was conducted primarily in urban and sub-
urban centers comprising the NETT spoke and hub
complexes. Study interventions occurred in ambulances,
and 33 emergency medical services (EMS) agencies
were involved. Patients were transported to 79 receiving
hospitals.
Adults and children with estimated body weights of
at least 13 kg who required treatment with benzodiaze-
pines for status epilepticus were eligible for inclusion.
Based on the previous experience of the Prehospital
Treatment of Status Epilepticus trial, we anticipated that
a reenrollment rate of up to 15% would be unavoid-
able.6
Study Protocol
A study box was used to distribute the study treatments
and record clinical events in the ambulance. Demo-
graphic data, vital signs, medical history, seizure recur-
rence, ED disposition, and hospital discharge data were
collected using predeﬁned procedures. Subjects with
repeat enrollments were followed for adverse events as
per the protocol and outcome data were collected, but
only the ﬁrst enrollment for each patient was included
in the primary outcome analysis.
Data Analysis
The primary analysis of the RAMPART trial used a one-
sided test for binomial proportions to test the noninferi-
ority hypothesis.7 A total of 1,024 patients were planned
for enrollment, which included an inﬂation factor to
account for a 15% repeat enrollment rate.
In the current investigation, we provide descriptive
statistics regarding the RAMPART subjects who
had repeat enrollments and assess the effect of account-
ing for these reenrollments in the analysis. In addition,
we summarize each event regarding treatment assign-
ment and treatment success graphically for these
subjects.
For this secondary analysis, generalized linear mixed
models with a logit link function were employed to esti-
mate the treatment effect accounting for the correlated
observations due to repeat enrollments.8 We ﬁt three
models: one with all RAMPART events included and
ignoring within-subject correlation (simple logistic
regression model); a second that accounts for clustering
within individuals using a generalized linear mixed
model; and a third mixed model, which excludes sub-
jects who had treatment assignment crossover in subse-
quent enrollments. The intraclass correlation coefﬁcient
(ICC) is deﬁned as the between subject variance divided
by the total variance or as the proportion of the total
variance attributed to clustering, in this case within
individuals.
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RESULTS
In the RAMPART trial, there were 1023 enrollments
among 893 unique individuals. From these 893 individu-
als there were 85 individuals accounting for 130 reen-
rollments (64 with two enrollments, 13 with three
enrollments, and eight ranged from four to 14). The
demographic and clinical characteristics of the reenroll-
ers are provided in Table 1.
Figure 1 shows the number of enrollments, treatment
assignments, and responses to treatment among the re-
enrollers. There was treatment crossover in 44 of the 85
reenrollers (52%). The treatment effect on the logit
scale, the standard error, test statistics, p-value, and
ICC for each model are provided in Table 2. Model 1
ignores within subject correlation and when compared
to the other methods, has the lowest standard error,
and as such is overstating the precision of the estimated
treatment effect by failing to account for repeated
observations within individuals. Models 2 and 3 use dif-
ferent methods for accounting for within subject corre-
lation; however, there is very little change in the
estimated treatment effect and a similarly small
decrease in the precision. Both the reduced sample size
and the accounting for within-subject correlation con-
tribute to the observed trends.
DISCUSSION
Repeat enrollments within the RAMPART trial were rel-
atively common, yet still below the projected proportion
of 15%. The RAMPART trial had a large treatment
effect and we estimated the ICC for Models 2 and 3 to
be quite low. As such, the conclusions of the trial would
have been unchanged if repeat enrollments were
included, with or without accounting for the correlation.
However, the interpretation of low versus high ICC val-
ues will vary based on the clinical setting and the design
setting. For RAMPART, we may have expected a higher
ICC value because the cluster is composed of repeated
measurements within a subject. This value may have
been diluted due to the majority of the subjects having
one outcome measure or one enrollment. Despite this,
the precision of the estimate of the treatment effect
Table 1
Characteristics and Outcomes of the Trial Participants by Repeat Enrollment Status
Characteristic Repeat Enrollers (n = 85) Single Enrollers (n = 808)
Age (yr), mean (SD) 43.36 (17.27) 43.43 (22.36)
Female 32 (37.65) 373 (46.16)
Ethnicity
Hispanic or Latino 13 (15.29) 93 (11.51)
Not Hispanic or Latino 52 (61.18) 548 (67.82)
Unknown 20 (23.53) 167 (20.67)
Race
American Indian or Alaska Native 0 (0.00) 8 (0.99)
Asian 1 (1.18) 21 (2.60)
Black or African American 51 (60.00) 402 (49.75)
Native Hawaiian or other Pacific Islander 1 (1.18) 2 (0.25)
White 29 (34.12) 319 (39.48)
More than one race 0 (0.00) 14 (1.73)
Other 1 (1.18) 8 (0.99)
Unknown 2 (2.35) 34 (4.21)
Received high dose (estimated weight > 13 kg) 78 (91.76) 694 (85.89)
Prior history of epilepsy
No 9 (10.59) 205 (25.37)
Yes 68 (80.00) 520 (64.36)
Not answered (not SE; one SE missing response) 8 (9.41) 83 (10.27)
Precipitant of episode
Anticonvulsant withdrawal or noncompliance 33 (38.82) 245 (30.32)
Idiopathic or refractory breakthrough 26 (30.59) 219 (27.10)
Acute threshold lowering comorbidity 8 (9.41) 52 (6.44)
Other or none identified* 18 (21.18) 292 (36.14)
Final diagnosis
Seizure/SE 77 (90.59) 726 (89.85)
Unable to determine 4 (4.71) 23 (2.85)
Nonepileptic spell 4 (4.71) 59 (7.30)
Intubation within 30 minutes of ED arrival 16 (18.82) 115 (14.23)
Seizures terminated without rescue therapy 57 (67.06) 554 (68.56)
Recurrent seizure 27 (31.76) 98 (12.13)
Hospitalized
No 37 (43.53) 299 (37.00)
Yes 48 (56.47) 502 (62.13)
Unknown 0 (0.00) 7 (0.87)
Data are n (%) unless otherwise noted.
SE = status epilepticus.
*Other precipitants include status without prior history, nonepileptic spell, and unable to determine.
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would have falsely increased if the correlation was
ignored, as the standard errors would be biased toward
smaller values.
While outside the scope of this design, it is well
known from animal and other data that status epilepti-
cus becomes harder to discontinue as it lasts longer and
becomes more established.9 Given variable recognition,
EMS activation, and EMS response times, it is plausible
that time to treatment may be a more important factor
than simply individual identity and disease phenotype.
The ethics of repeatedly enrolling a patient in a clini-
cal trial deserve some mention. Because this trial was
conducted in an emergency situation under EFIC, each
seizing patient needed to be treated quickly. The pri-
mary method by which a subject could opt out of the
trial was via a bracelet. While not part of the protocol
or manual of procedures, the study teams involved with
the care of patients with large numbers of enrollments
took a great deal of time attempting to arrange follow-
up for the frequent reenrollers in many cases. Opt-out
bracelets were repeatedly given in some cases. Because
RAMPART compared two therapies already in clinical
use, all subjects, including those enrolled more than
once, always received active treatment consistent with
existing standard care. Due to the standard trial proce-
dure of only using the ﬁrst event per subject, these sub-
jects were exposed to research procedures repeatedly,
while not contributing additional primary outcome data.
These subjects did provide additional safety data, along
with the data used by the current report to estimate the
effect of repeat enrollment.
Our ﬁndings also have implications for clinical care
and further research in status epilepticus. Although the
intent of this analysis was merely to explore the statisti-
cal effect of how reenrollers were handled in RAM-
PART, we are also able to generate hypotheses related
to the associations seen. Second, there was a small but
potentially important subset of reenrollers who appear
to be consistently refractory to initial benzodiazepines.
Improving the initial care of this subset may involve
Table 2
Trial Treatment Effect and Within-subject Correlation Estimates Using Different Methods
Scenario
Treatment
Effect
Standard
Error
Test
Statistic p-value ICC
Model 1: treatment effect ignoring ICC 0.5493 0.1358 16.36 <0.0001 NA
Model 2: accounting for repeat enrollments but ignoring treatment
assignment crossover
0.5590 0.1388 15.76 0.0001 0.119
Model 3: accounting for repeat enrollments but deleting the 44 subjects
that had treatment assignment crossover (895 enrollments; 849 unique
subjects)
0.5560 0.1477 14.16 0.0005 0.094
Treatment effect is parameter estimate and standard error on logit scale. For example, parameter estimate of 0.55 corresponds
to OR of 1.7.
ICC = intraclass correlation coefficient.
Figure 1. Unique treatment and outcome patters for reenrollers. Each row represents all the unique sequences of treatments and
their outcomes that occurred during the trial followed on the right side by the number of subjects who experienced that pattern.
Column 1 represents each subject’s first enrollment, column 2 the next enrollment, etc. IM = intramuscular; IV = intravenous.
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earlier addition of a nonbenzodiazepine anticonvulsant
medication, rather than simply optimizing ﬁrst-line ben-
zodiazepine administration. Future trials investigating
this possibility are warranted.
LIMITATIONS
The data used for this analysis were collected from a
single clinical trial in status epilepticus comparing two
benzodiazepines. The degree to which the results may
apply to other conditions and the testing of other treat-
ments is unknown. Second, the majority of patients
enrolled in RAMPART came from urban areas, with a
signiﬁcant plurality from metro Detroit and greater Cin-
cinnati. The degree to which the epidemiology of epi-
lepsy may vary across the United States is outside the
scope of this work, but could have potentially inﬂuenced
the results if subjects from areas oversampled in RAM-
PART are not generally representative.
CONCLUSIONS
In general, excluding repeat enrollments at the analysis
phase is a conservative strategy, particularly in clinical
trials of emergency conditions with interval complete
resolution. Inﬂation of the required sample size during
the planning stages is necessary in order to account for
these postrandomization exclusions. The RAMPART
experience demonstrates that exclusion may not always
be necessary, but also allows exploration of alternative
measures that can be taken at relatively low statistical
cost when independence of observations cannot be
assumed. If the expected intraclass correlation coefﬁ-
cient was known prior to the planning of RAMPART,
the sample size could have been inﬂated by this factor
to account for the correlation at the study planning
stages. In summary, we recommend that steps be taken
to account for repeat enrollments in emergency trials
and encourage other investigators to evaluate and pub-
lish the intraclass correlation coefﬁcient values to allow
for the more quantitative planning of future trials in
such conditions.
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Supporting Information
The following supporting information is available in the
online version of this paper:
Data Supplement S1. Detailed methods.
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